7:00-8:00  Industry Sponsored Breakfast Program
ERLEADA™ (apalutamide) for the Treatment of Patients with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

**Speaker:** Jonathan Henderson, MD, *Janssen Pharmaceuticals*

8:00 - 8:05  Introduction - Ajay Singla, MD, Harvard University, Boston, MA

8:05 - 8:55  Prostate Cancer

**Moderators:**
Ashok Hemal, MD, Wake Forest University School of Medicine, Winston Salem, NC
Ravindra Sabnis, MD, Muljibai Patel Urological Hospital, Nadiad, India
1. Tissue Based Genomic Biomarkers in Low Risk Prostate Cancer: Can They Predict the Presence of Higher Grade Disease– Ganesh Palapattu, MD, University of Michigan Urology Center, Ann Arbor, MI
2. Active Surveillance in which Patients – Ganesh Raj, MD, PhD, University of Texas, Dallas, TX
3. Focal Therapy for Localized Prostate Cancer (HIFU, Cryotherapy) – Alok Srivastava

8:55 - 9:45  Small Renal Masses

**Moderator:** Monish Aron, MD, Los Angeles, CA
1. Observation Versus Biopsy – Ravi Munver, MD, Hackensack Medical Center, Hackensack, NJ
2. Ablative Therapy (RFA, Cryotherapy) – Ramakrishna Venkatesh, MD, Washington University, St. Louis, MO
3. Partial Nephrectomy – Mihir Desai, Beachwood, OH

9:45 – 10:00  IAUASakti Das Research Scholar Presentations

**Moderator:** Harcharan Gill, MD, Stanford University Hospital, Stanford, CA
Rita Verma, PhD, Cincinnati, OH
Arjun Sivaraman, MD, Memorial Sloan Kettering Cancer Center, New York, NY

10:00 – 10:30  Coffee Break

10:30 – 11:00  Refractory Overactive Bladder

**Moderators:** Anurag Das, MD, Harvard University, Boston, MA
Ajit Vaze, MD, Mumbai, India
1. For – onabotulinumtoxin
2. A – Priya Padmanabh, MD, Kansas City, KS
3. For – Neuromodulation – Priyanka Gupta, MD, University of Michigan, Ann Arbor, MI

11:00 – 11:30  Renal Stone Disease for 1.5 cm Lower Pole Stone- Debate

**Moderators:** Ojas Shah, MD, Columbia University Medical Center, New York, NY
Rajeev TP, MBBS, M.S., M.Ch, Gauhati Medical College Hospital, Gauhati, India
1. For- Ureteroscopy – Sri Sivalingam, MD, Cleveland Clinic, OH
2. For – PCNL – Mantu Gupta, MD, Larchmont, NY
11:30 – 11:45  USI Talk – “Overview of Female Urology and Current Status in India” – Ajit Vaze, MD, Mumbai, India  
**Moderator:** Ajay Singla, MD, Harvard University, Boston, MA

11:45 – 12:00  Penile Rehabilitation after Prostate Cancer Treatment – Ranjith Ramasamy, MD, University of Miami, Miami FL  
**Moderator:** Joseph Alukal, MD, New York, NY

12:00 – 1:00  **Industry Sponsored Lunch Program**  
Understanding Legal Tools: The Keys to Lawsuit Prevention, License Protection and Tax Reduction  
**Speaker:** Art McOmber, B.A., *Legally Mine, Inc.*

1:00 – 1:30  IAUA Business Meeting

1:30 – 2:00  **Poster Presentation**  
**Moderators:** Puneet Sidhwani, MD, University of Toledo, Toledo, OH

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
</table>
| 1. | **Is There a Need to Revisit Surveillance Cystoscopy Protocol for pTa Grade 1/Grade 2/Low Grade Bladder Tumors Receiving Immediate Single Instillation Intravesical Mitomycin C?**  
Authors: Nitin Sudhakar Kekre, Santhosh Nagasubramanian, Anuj Deep Dangi, Chandrasingh J., Antony Devasia, Santosh Kumar |
| 2. | **Analysis of Surgical Re-exploration in Renal Transplant Recipients in a High Volume Centre – A Plea for Early Intervention!**  
Authors: Feroz Zafar, Ashwin Mallya, Indraneel Banerjee, Tarun Jindal, Rohan Nautiyal, Prasun Ghosh, Rajesh Ahlawat |
| 3. | **Urine Culture: Do we get Satisfactory Results?**  
Author: Pankaj Maheshwari |
| 4. | **Can we Predict & Prevent Postoperative Complications in Percutaneous Nephrolithotomy?**  
Authors: Aditya Ylikar, Amish Mehta, Jitendra Amlani, Vivek Joshi |
| 5. | **Laparoscopic Pyelolymphatic Disconnection for Refractory Chyluria**  
Authors: Bhupendra Pal Singh, Hemant R. Pathak, Vikas Kumar, Satya Narayan Sankhwar |
| 6. | **Role of PCR in Early Diagnosis of Male Genital Tuberculosis**  
Authors: Kiran Chawla, Arun Chawla, Padmaraj Hegde |
| 7. | **Reliability of Imaging Modalities for Lymph Node Positivity in Prostate Cancer; Correlation with Histopathology**  
Authors: Ganesh Bakshi, Amitesh Anand, Gagan Prakash, Mahendra Pal |
| 8. | **Thrombosis in Emphysematous Pyelonephritis can be significant**  
Authors: Manitur Raghavendran, Kiran G Kumar, Venugopal A |
INDIAN AMERICAN UROLOGICAL ASSOCIATION
Annual Meeting • San Francisco, CA
Friday, May 18, 2018
Moscone Center South, Room 216

AUA ACCREDITATION INFORMATION
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

AUA PARTICIPANT INFORMATION & POLICIES
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Consent to Use of Photographic Images: Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA’s use and distribution (both now and in the future) of the attendee’s image or voice in photographs and electronic reproductions of such meetings and activities.

Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.